Similar articles

• The cellular and molecular basis of heart failure in regurgitant valvular diseases: the myocardial extracellular matrix as a building block for future therapy.

  Borer JS, Truter SL, Herrold EM, Supino PG, Carter JN, Gupta A. Borer JS, et al. Adv Cardiol. 2002;39:7-14. doi: 10.1159/000058906. Adv Cardiol. 2002. PMID: 12060925 Review. No abstract available.
• Potential role of fibrosis imaging in severe valvular heart disease.

  Debonnaire P, Delgado V, Bax JJ. Debonnaire P, et al. Heart. 2015 Mar;101(5):397-407. doi: 10.1136/heartjnl-2013-304679. Epub 2014 Jun 12. Heart. 2015. PMID: 24924620 No abstract available.
• Valve replacement for regurgitant lesions of the aortic or mitral valve in advanced left ventricular dysfunction.

  Bonow RO, Nikas D, Elefteriades JA. Bonow RO, et al. Cardiol Clin. 1995 Feb;13(1):73-83, 85. Cardiol Clin. 1995. PMID: 7796434 Review.
• [Histometrical estimation of the left ventricular hypertrophy in aortic insufficiency (author's transl)].

  Kawamura K, Yamate N, Shoji T. Kawamura K, et al. Kokyu To Junkan. 1982 Jun;30(6):649-52. Kokyu To Junkan. 1982. PMID: 6213992 Japanese. No abstract available.
• Should valvular replacement be reserved for symptomatic aortic valve disease?

  Reul GJ Jr, Cooley DA. Reul GJ Jr, et al. Cardiovasc Clin. 1977;8(1):279-300. Cardiovasc Clin. 1977. PMID: 849596 No abstract available.